CClinicalTrials.gg
CompletedNCT00951925Updated Mar 6, 2019

Protocol to Obtain Bone Marrow for Research

An observational study in Bone Marrow Biopsy, sponsored by Dartmouth-Hitchcock Medical Center. Completed at 1 site in United States. Open to participants aged 17 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-06.

Sponsored by Dartmouth-Hitchcock Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
28
Ages
17 Years and older
Sex
All
01

Study summary

Potential donors who are undergoing bone marrow biopsy or bone marrow donation as part of clinical care will be asked by the principal investigator (PI) if they might be interested in donating marrow for this research project. If they are interested, the PI will meet with the prospective donor to review the information contained in the informed consent document and to answer any questions the potential subject may have. Bone marrow aspirates of approximately 5cc will be obtained from the posterior iliac crest of subjects using standard techniques.

Read the detailed description

The purpose of this study is to determine the mechanisms that regulate human globin gene expression by analyzing the function of cell signaling pathways and the expression of other related genes and their protein products in the bone marrow cells of people without blood diseases. This includes the effects of drugs and other in vitro manipulations of the cells once they are removed from donors. These assays will include, but are not limited to, determinations of DNA methylation status, histone acetylation profiles, DNAse sensitivity, transcription factor binding to DNA, levels of various proteins, messenger RNAs and miRNAs in the cells of the marrow samples. By understanding how this process occurs in people without blood diseases, we hope to to design future treatments for people with diseases such as sickle cell disease and B-thalassemia.

02

Conditions studied

  • Bone Marrow Biopsy

Keywords

  • diagnostic bone marrow biopsies
  • bone marrow harvesting for autologous BMT
03

In context

Lead sponsor

Dartmouth-Hitchcock Medical Center is the lead sponsor of 472 studies on the registry; 68 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 20 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  • Patients undergoing diagnostic bone marrow biopsies at the Norris Cotton Cancer Center of Dartmouth Hitchcock Medical Center (DHMC).
  • Patients undergoing bone marrow harvesting for autologous bone marrow transplantation.

Inclusion criteria

  • Patients undergoing diagnostic bone marrow biopsies at the Norris Cotton Cancer Center of DHMC.
  • Patients undergoing bone marrow harvesting for autologous bone marrow transplantation.
  • Normal donors undergoing bone marrow harvesting for autologous bone marrow transplantation.
  • Normal persons over the age of 17 who volunteer to undergo bone marrow aspiration.

Exclusion criteria

Exclusion Criteria:

  • Normal volunteers with known allergies to lidocaine (or similar analgesics)or betadine.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
28 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • No Treatment

    Other: Bone Marrow Aspirate Draw

Interventions

  • OtherBone Marrow Aspirate Draw

    5cc of Bone Marrow Aspirate will be drawn

06

What researchers measure

Primary outcomes

  1. Regulation of human globin gene expression

    The purpose of this study is to determine the mechanisms that regulate human globin gene expression by analyzing the function of cell signaling pathways and the expression of other related genes and their protein products in the bone marrow cells of people without blood diseases.

    Time frame: Ongoing

07

Study locations

1 site
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00951925
Lead sponsor
Dartmouth-Hitchcock Medical Center
Responsible party
Christopher H. Lowrey (Professor of Medicine and of Pharmacology and Toxicology, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Aug 4, 2009
Start date
Jun 2005
Primary completion
Dec 2016
Completion
Dec 2018
Last update
Mar 6, 2019

Study contacts

Christopher H Lowrey, MD
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion